Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqCM:VBIV
VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
VBI Vaccines (NASDAQ:VBIV) Full Year 2022 Results
Key Financial Results
- Net loss: US$113.3m (loss widened by 62% from FY 2021).
- US$0.44 loss per share (further deteriorated from US$0.27 loss in FY 2021).
VBIV Products In Clinical Trials
- Phase I: 5.
- Phase II: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
VBI Vaccines Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 31%.
Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 5.1% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with VBI Vaccines (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process.
What are the risks and opportunities for VBI Vaccines?
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
Rewards
Trading at 77.5% below our estimate of its fair value
Revenue is forecast to grow 58.23% per year
Risks
Has less than 1 year of cash runway
Does not have a meaningful market cap ($78M)
Does not have meaningful revenue ($1M)
Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
VBI Vaccines
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:VBIV
VBI Vaccines
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
Good value with mediocre balance sheet.
